1 | DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. 2022;27:940 doi: 10.1093/oncolo/oyac161 |
2 | Novel targets in the treatment of neuroendocrine tumors: RBP2. 2017;4:31 doi: 10.2217/ije-2016-0022 |
3 | PredictingIn VivoEfficacy fromIn VitroData: Quantitative Systems Pharmacology Modeling for an Epigenetic Modifier Drug in Cancer. 2020;13:419 doi: 10.1111/cts.12727 |
4 | Patient-derived lung cancer organoids as in vitro cancer models for therapeutic screening. 2019;10: doi: 10.1038/s41467-019-11867-6 |
5 | The Expression of Chromogranin A, Syanptophysin and Ki67 in Detecting Neuroendocrine Neoplasma at High Grade Colorectal Adenocarcinoma. 2021;9:1142 doi: 10.3889/oamjms.2021.7419 |